Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 2, 2026
- Syndax Pharmaceuticals appointed Aaron A. Ondrey CFO effective November 9, 2026, succeeding retiring Keith A. Goldan. Ondrey receives a $543,000 annual salary, 45% target bonus and option for 270,000 shares.
- 10-Q report · filed Nov 2, 2026
- Syndax reported third-quarter Revuforj net revenue of $60.7 million, up 90%, and Niktimvo net revenue of $67.4 million, up 47%. MAXPIRe missed its primary endpoint in IPF, and Syndax does not plan to move forward with further axatilimab development there.
The audio replay and transcript follow the call.